Inglis Tiffany Eul Davis 4

What Happened

• Inglis Tiffany Eul Davis, Chief Medical Officer of SERA Prognostics, received equity awards on 2026-03-12: 17,437 restricted stock units (RSUs) and 27,034 derivative awards (stock options). Both grants show $0 cash paid in the report (they are compensation grants, not open-market trades).

Key Details

• Transaction date(s): 2026-03-12; Form 4 filed 2026-03-13 (timely).
• Prices: $0.00 reported (awarded, not purchased).
• Vesting/terms:
  • RSUs (17,437): vest over four years — 1/16 of the original grant vests in quarterly installments starting on the vesting commencement date of March 10, 2026, subject to continued service. (Footnote F1)
  • Stock options (27,034): vest over four years — 1/48 of the original grant vests in monthly installments starting on March 10, 2026, subject to continued service. (Footnote F2)
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported promptly the next day; no late-filing flag indicated.

Context

• These awards are compensation grants (not purchases or sales). RSUs convert to actual shares as they vest; options must be exercised (and may require payment of a strike price) before becoming shares. There is no indication the grants were immediately sold or exercised. These kinds of awards are routine executive compensation and do not by themselves indicate buying or selling sentiment.